Study of the Safety, Reactogenicity and Immunogenicity of "EpiVacCorona" Vaccine for the Prevention of COVID-19

PHASE1,PHASE2

Phase

COMPLETED

Status

100

Enrollment

OTHER_GOV

Sponsor class

Conditions

BIOLOGICAL: EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)
OTHER: Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%)

Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"